By Ambrose O’Callaghan
After a period of underperformance, healthcare is showing signs of a meaningful turnaround. The S&P 500 Healthcare Index has staged an impressive rebound since the beginning of September, gaining further momentum into the month of November. The sector is up 12.12% in the quarter-to-date, bringing its year-to-date return to 21.93% as of November 11, 2026. This represents a notable change in market leadership and a potential turning point for an area that investors had largely overlooked.

Source: S&P 500 Health Care Sector (^SP500-35), price return, Dec. 31, 2025 to Nov. 11, 2026. Data: Yahoo Finance, Barchart, MarketScreener, Investing.com and YCharts; Nov. 11 level estimated from reported sector moves
A rotation in market leadership
A major catalyst has been a broader rotation away from the technology-heavy names that dominated much of the market’s performance earlier in 2026. Over the same quarter-to-date period, the S&P 500 Information Technology Index is down 9.65%, and the S&P 500 Communication Services Index has fallen 10.76% as of close on November 11, 2026.
Investors have increasingly looked toward companies with established earnings, resilient demand, and attractive growth prospects. Healthcare offers an interesting combination of all three.
Healthcare giants leading the charge
Few companies better illustrate healthcare’s growth potential than Eli Lilly. Its weight-loss and diabetes treatments, Mounjaro and Zepbound, continue to drive exceptional revenue growth. In its October 29 earnings release, Eli Lilly reported third-quarter revenue of US$24.4 billion – up 39% year over year. Strong demand prompted management to raise its full-year revenue guidance to between US$91 billion and $92 billion. The company’s expanding obesity-drug portfolio, including its newer oral treatment Foundayo, also provides additional growth opportunities.
Meanwhile, UnitedHealth Group has offered another important catalyst. After facing considerable operating challenges, the healthcare giant reported stronger-than-expected third-quarter results on October 13 and raised its full-year adjusted earnings outlook to at least $20.50 per share. Improvements in medical cost management, pricing discipline, and operating efficiency have helped support its turnaround. While challenges remain, the results provided investors with encouraging evidence that the business is making progress.
Canada’s Largest Healthcare Income ETFs | HHL & HHLE
The Harvest Healthcare Leaders Income ETF (TSX: HHL) is an equally weighted portfolio of 20 large-cap global healthcare companies, selected for their potential to provide attractive monthly income and long-term growth. To generate an enhanced monthly distribution yield, an active covered call strategy is engaged.
Annualized Performance
As at 2026/10/31
| Ticker | 1M | 3M | 6M | YTD | 1Y | 2Y | 3Y | 4Y | 5Y | 7Y | 8Y | 10Y | 11Y | SI |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HHL | 7.05 | 9.42 | 17.05 | 8.91 | 15.17 | 6.62 | 11.61 | 8.28 | 7.33 | 9.52 | 8.84 | 9.12 | 7.72 | 7.30 |
| HHL.B | 5.28 | 9.55 | 21.50 | 12.50 | 16.86 | 8.70 | 13.53 | 10.31 | 11.14 | - | - | - | - | 11.32 |
| HHL.U | 7.28 | 9.95 | 18.16 | 10.55 | 17.35 | 8.53 | 13.26 | 9.62 | 8.49 | 10.67 | 9.97 | - | - | 9.85 |
This month, HHL.U was awarded an LSEG Lipper Fund Award for 2026:
- LSEG Lipper Fund Awards Winner [Canada] 2026 Winner, Harvest Healthcare Leaders Income ETF, Class U, 5 years
The LSEG Lipper Awards celebrate funds and fund management firms that excel in delivering strong, risk-adjusted performance relative to their peers. HHL.U was honoured for its innovative approach that combines exposure to a portfolio of top healthcare companies with an active covered call strategy, designed to enhance income while managing volatility.
“The 2026 LSEG Lipper Fund Awards mark another volatile three-year stretch for global markets,” said Otto Christian Kober, Head of Lipper Research at LSEG Data & Analytics. “The managers we’re recognizing have guided investors through an environment where base rates have spiked, then diverged, as central banks navigated new and challenging inflationary landscapes, alongside uneven global growth and heightened geopolitical risk. Whether managers entered the market in the era of easy money or have navigated cycles for decades, this most recent period made one thing plain: durable results come form a disciplined process, not prediction.”
For investors who are seeking even higher levels of income, the Harvest Healthcare Leaders Enhanced Income ETF (TSX: HHLE) is built to deliver enhanced income and growth opportunities by applying modest leverage to an investment in HHL.
Annualized Performance
As at 2026/10/31
Conclusion
Healthcare’s recent resurgence is an encouraging reminder of the opportunities that can emerge when market leadership begins to broaden. Strong performances from industry leaders like Eli Lilly and UnitedHealth, combined with renewed investor interest and improving fundamentals, have helped put the sector back in the spotlight.
For investors looking to diversify beyond the market’s technology-heavy concentration while maintaining exposure to long-term growth opportunities, healthcare offers an attractive combination of innovation, resilient demand, and income potential. Through HHL and HHLE, investors can access some of the world’s leading healthcare companies while pursuing regular monthly income and long-term portfolio growth.
Disclaimer
For Information Purposes Only. All comments, opinions and views expressed are of a general nature and should not be considered as advice and/or a recommendation to purchase or sell the mentioned securities or used to engage in personal investment strategies.
The views and/or opinions expressed above are of a general nature and are for informational purposes only. The contents should not be considered as advice and/or a recommendation to purchase or sell the mentioned securities or used to engage personal investment strategies. Investors should consult their investment advisor before making any investment decision.
Commissions, management fees and expenses all may be associated with investing in Harvest Exchange Traded Funds (managed by Harvest Portfolios Group Inc. (the “Funds”). The funds are not guaranteed, their values change frequently and past performance may not be repeated. Please read the relevant prospectus before investing.
The indicated rates of return are the historical annual compounded total returns (except for figures of one year or less, which are simple total returns) including changes in unit value and reinvestment of all distributions and do not take into account sales, redemption, distribution or optional charges or income taxes payable by any securityholder that would have reduced returns.
LSEG Lipper Fund Awards, © 2026 LSEG. All rights reserved. Used under license. The LSEG Lipper Fund Awards, granted annually, highlight funds and fund companies that have excelled in delivering consistently strong risk-adjusted performance relative to their peers. The LSEG Lipper Fund Awards are based on the Lipper Leader for Consistent Return rating, which is a risk-adjusted performance measure calculated over 36, 60 and 120 months. The fund with the highest Lipper Leader for Consistent Return (Effective Return) value in each eligible classification wins the LSEG Lipper Fund Award. For more information, see lipperfundawards.com. Although LSEG makes reasonable efforts to ensure the accuracy and reliability of the data contained herein, their accuracy is not guaranteed by LSEG Lipper. Find out more at www.lipperfundawards.com. LSEG Lipper Fund Awards 2026 Canada Winner, Harvest Healthcare Leaders Income ETF (Class U), Best Health Care Equity Fund over five years, out of a total of 12 funds.
